Sound Income Strategies LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 11.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,857 shares of the company’s stock after selling 1,257 shares during the quarter. Johnson & Johnson accounts for 0.6% of Sound Income Strategies LLC’s investment portfolio, making the stock its 19th largest position. Sound Income Strategies LLC’s holdings in Johnson & Johnson were worth $1,271,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the business. Selective Wealth Management purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at $105,000. Fusion Family Wealth LLC grew its position in Johnson & Johnson by 621.4% during the 2nd quarter. Fusion Family Wealth LLC now owns 1,010 shares of the company’s stock worth $123,000 after purchasing an additional 870 shares during the last quarter. Ifrah Financial Services Inc. purchased a new position in Johnson & Johnson during the 3rd quarter worth $203,000. Exane Asset Management purchased a new position in Johnson & Johnson during the 2nd quarter worth $206,000. Finally, Peak Capital Management LLC purchased a new position in Johnson & Johnson during the 2nd quarter worth $207,000. Institutional investors own 67.28% of the company’s stock.
Several research analysts have issued reports on JNJ shares. Citigroup lowered their price objective on shares of Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 2nd. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $164.00 target price for the company in a research note on Wednesday, December 12th. Morgan Stanley set a $140.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Thursday, December 20th. Finally, Wells Fargo & Co reiterated an “outperform” rating and issued a $152.00 price objective (down previously from $162.00) on shares of Johnson & Johnson in a research note on Monday, January 14th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $142.81.
Shares of JNJ opened at $136.61 on Tuesday. The company has a quick ratio of 1.20, a current ratio of 1.47 and a debt-to-equity ratio of 0.46. The stock has a market cap of $367.32 billion, a price-to-earnings ratio of 16.70, a price-to-earnings-growth ratio of 2.10 and a beta of 0.68. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.99.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, January 22nd. The company reported $1.97 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.02. The business had revenue of $20.39 billion during the quarter, compared to the consensus estimate of $20.27 billion. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The company’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.74 earnings per share. As a group, research analysts anticipate that Johnson & Johnson will post 8.57 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, March 12th. Investors of record on Tuesday, February 26th were issued a $0.90 dividend. The ex-dividend date was Monday, February 25th. This represents a $3.60 dividend on an annualized basis and a yield of 2.64%. Johnson & Johnson’s payout ratio is 44.01%.
Johnson & Johnson declared that its Board of Directors has authorized a share repurchase plan on Monday, December 17th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 1.5% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: Economic Reports
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.